Matching articles for "zolpidem"
Issue 1667 · January 9, 2023
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

View the Expanded Table: Some Oral Drugs for Chronic Insomnia

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e6-10 doi:10.58347/tml.2023.1667b
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Issue 1667 · January 9, 2023
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Issue 1654 · July 11, 2022
Daridorexant (Quviviq) for Insomnia

The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):107-10
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Issue 1601 · June 29, 2020
Lemborexant (Dayvigo) for Insomnia

The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be…

Med Lett Drugs Ther. 2020 Jun 29; 62(1601):97-100
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant ( Belsomra ) was the first.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1562 · December 17, 2018
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Issue 1562 · December 17, 2018
Expanded Table: Some Oral Hypnotics for Insomnia (online only)

View the Expanded Table: Some Oral Hypnotics for Insomnia

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):e209-13
View the Expanded Table: Some Oral Hypnotics for Insomnia
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 1466 · April 13, 2015
Advice for Travelers

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
Issue 1463 · March 2, 2015
Suvorexant (Belsomra) for Insomnia

The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):29-31
The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Issue 1444 · June 9, 2014 Free
In Brief: Lowering the Dose of Lunesta

The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):48
The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours. 1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem ( Ambien , and generics) and zaleplon ( Sonata , and generics). All benzodiazepine receptor agonists may impair performance the next morning, including driving. 2 Anterograde amnesia and complex sleep-related behaviors without conscious awareness may also occur. Hallucinations have been reported. Like the benzodiazepines, benzodiazepine receptor agonists are schedule IV controlled substances; withdrawal, dependence, and abuse can occur. 1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. Available at www.fda.gov. Accessed May 29, 2014. 2. Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57. Download complete U.S. English article
Issue 1408 · January 21, 2013
FDA Requires Lower Dosing of Zolpidem

On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien , Ambien CR , Edluar and Zolpimist , which are all approved for…

Med Lett Drugs Ther. 2013 Jan 21; 55(1408):5
On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien , Ambien CR , Edluar and Zolpimist , which are all approved for treatment of insomnia, to lower the doses for women and to recommend in their labeling consideration of a lower dose for men. No change will be required in the dose of Intermezzo , a low-dose sublingual formulation of zolpidem for middle-of-the-night awakening, which is already recommended in a lower dose for women.
Issue 119 · July 1, 2012
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.

Treat Guidel Med Lett. 2012 Jul; 10(119):57-60
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Issue 1387 · April 2, 2012
Low-Dose Sublingual Zolpidem (Intermezzo) for Insomnia due to Middle-of-the-Night Awakening

The FDA has approved a new low-dose sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem tartrate ( Intermezzo – Transcept/Purdue) for treatment of insomnia due to…

Med Lett Drugs Ther. 2012 Apr 2; 54(1387):25-6
The FDA has approved a new low-dose sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem tartrate ( Intermezzo – Transcept/Purdue) for treatment of insomnia due to middle-of-the-night awakening. Ambien and other zolpidem formulations available in the US are labeled for use only at bedtime.
Issue 1384 · February 20, 2012
Zolpidem Oral Spray (Zolpimist) for Insomnia

Zolpidem oral spray ( Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate ( Ambien , and others), has been approved by the FDA for short-term treatment of insomnia…

Med Lett Drugs Ther. 2012 Feb 20; 54(1384):14-5
Zolpidem oral spray ( Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate ( Ambien , and others), has been approved by the FDA for short-term treatment of insomnia characterized by difficulty falling asleep.
Issue 1348 · October 4, 2010
Low-Dose Doxepin (Silenor) for Insomnia

The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this…

Med Lett Drugs Ther. 2010 Oct 4; 52(1348):79-80
The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.
Issue 1336 · April 19, 2010
Edluar - A New Sublingual Formulation of Zolpidem

Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem ( Ambien , and others), has been approved by the FDA for treatment of insomnia.

Med Lett Drugs Ther. 2010 Apr 19; 52(1336):29-30
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem ( Ambien , and others), has been approved by the FDA for treatment of insomnia.
Issue 87 · November 1, 2009
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases…

Treat Guidel Med Lett. 2009 Nov; 7(87):83-94
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 79 · March 1, 2009
Drugs for Insomnia

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar; 7(79):23-6
The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 42 · February 1, 2006
Drugs for Insomnia

Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than…

Treat Guidel Med Lett. 2006 Feb; 4(42):5-10
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than treatment with drugs. Hypnotic drugs are generally FDA-approved only for short-term use, but in practice they often are taken much longer.
Issue 1223 · December 5, 2005
Ambien CR for Insomnia

Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):97-8
Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received FDA approval to market an extended-release formulation of the drug, Ambien CR . The pharmacological rationale for doing so is that short-acting hypnotics like zolpidem are more effective at inducing sleep than they are at maintaining it.
Issue 1221 · November 7, 2005
Ramelteon (Rozerem) for Insomnia

Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which…

Med Lett Drugs Ther. 2005 Nov 7; 47(1221):89-91
Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.
Issue 1203 · February 28, 2005
Eszopiclone (Lunesta), a New Hypnotic

Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):17-9
Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem ( Ambien ) or zaleplon ( Sonata ), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.
Issue 1195 · November 8, 2004
Tablet Splitting

Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose…

Med Lett Drugs Ther. 2004 Nov 8; 46(1195):89-91
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose between marketed strengths. When 2 tablet sizes cost the same, as they often do, splitting the larger size saves money. Is this a reasonable practice?
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1093 · November 27, 2000
Drugs that may cause Cognitive Disorders in the Elderly

Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic…

Med Lett Drugs Ther. 2000 Nov 27; 42(1093):111-2
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
Issue 1084 · August 7, 2000
Hypnotic Drugs

Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be…

Med Lett Drugs Ther. 2000 Aug 7; 42(1084):71-2
Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective than drugs.
Issue 1063 · October 8, 1999
Zaleplon for Insomnia

Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.

Med Lett Drugs Ther. 1999 Oct 8; 41(1063):93-4
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Issue 978 · July 5, 1996
Hypnotic Drugs

Superseded by Drugs of Choice Handbook Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including…

Med Lett Drugs Ther. 1996 Jul 5; 38(978):59-61
Superseded by Drugs of Choice Handbook Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including five benzodiazepines and zolpidem ( Ambien ), a non-benzodiazepine that binds to benzodiazepine receptors in the brain. Some drugs marketed for other indications, such as antihistamines, antidepressants and antipsychotics, are also used as hypnotics. For many patients, nonpharmacological treatment of insomnia may be more effective than drugs, especially in the long term (CM Morin et al, Am J Psychiatry, 151:1172, 1994).